© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.
Researchers presented results from various studies on hepatitis C treatment and care at a medical conference in Seattle.
People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug inte...
Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.
Twelve weeks of Gilead Sciences newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in...
The Sovaldi/ledipasvir combination pill to treat hepatitis C does not have a clinically significant impact on five common HIV antiretrovirals.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
